Brace Yourselves for the Libertarian Tech Bro Takeover of the FDA

Two of Peter Thiel’s Silicon Valley cronies appear to be among Trump’s top choices for agency head.

<a href="http://www.istockphoto.com/photo/child-with-stomach-pain-gm468502327-34696976?st=_p_food%20poisoning">vitapix</a>/iStock

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


President-elect Donald Trump is taking his time choosing a nominee for secretary of the US Department of Agriculture—it’s the last open Cabinet post. But the USDA isn’t the only federal agency that lacks a proposed incoming leader just a week ahead of Inauguration Day. And while candidates for the USDA post have streamed thorough Trump Tower and Mar-a-Lago to plead their case, the Trump team has revealed little about whom it’s considering to head the Food and Drug Administration.

O’Neill declared that the FDA should stop requiring drug makers to prove their products actually work—”Let’s prove efficacy after they’ve been legalized,” he said. 

Until Thursday. Stat News reports that two Silicon Valley titans, Jim O’Neill and Balaji Srinivasan, met with Trump on January 12 to “discuss running the agency.” Neither are medical doctors or scientists—the typical backgrounds for most previous FDA commissioners. Rather, they’re tech guru-investors who espouse virulently libertarian views, including disdain for the FDA’s role in regulating the pharmaceutical industry.

O’Neill is a managing director of Mithril Capital, an investment firm founded by Peter Thiel, himself a hyperlibertarian investor and an early supporter of Trump’s candidacy. In a 2014 speech before a biotechnology group, O’Neill declared that the FDA should stop requiring drug makers to prove their products actually work—”Let’s prove efficacy after they’ve been legalized,” he said. 

Srinivasan, co-founder of the bitcoin startup 21.co and a partner at the venture capital firm at Andreessen Horowitz, has opined that information technology makes the FDA role in drug regulation obsolete:

Srinivasan, too, is associated with Thiel, who is an investor in Srinivasan’s bitcoin firm.

Neither Srinivasan nor O’Neill has said much publicly about the FDA’s other policy portfolio: overseeing food safety, including recently enacted rules designed to push the meat industry to rely less on antibiotics necessary for human medicine.

Trump himself has been opaque on the question of food safety regulations—though back in September, his campaign website did post, and quickly remove, a “fact sheet” denouncing the “FDA food police.”

WE CAME UP SHORT.

We just wrapped up a shorter-than-normal, urgent-as-ever fundraising drive and we came up about $45,000 short of our $300,000 goal.

That means we're going to have upwards of $350,000, maybe more, to raise in online donations between now and June 30, when our fiscal year ends and we have to get to break-even. And even though there's zero cushion to miss the mark, we won't be all that in your face about our fundraising again until June.

So we urgently need this specific ask, what you're reading right now, to start bringing in more donations than it ever has. The reality, for these next few months and next few years, is that we have to start finding ways to grow our online supporter base in a big way—and we're optimistic we can keep making real headway by being real with you about this.

Because the bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

payment methods

WE CAME UP SHORT.

We just wrapped up a shorter-than-normal, urgent-as-ever fundraising drive and we came up about $45,000 short of our $300,000 goal.

That means we're going to have upwards of $350,000, maybe more, to raise in online donations between now and June 30, when our fiscal year ends and we have to get to break-even. And even though there's zero cushion to miss the mark, we won't be all that in your face about our fundraising again until June.

So we urgently need this specific ask, what you're reading right now, to start bringing in more donations than it ever has. The reality, for these next few months and next few years, is that we have to start finding ways to grow our online supporter base in a big way—and we're optimistic we can keep making real headway by being real with you about this.

Because the bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate